Vergelijking

Petrelintide vs. Semaglutid

Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.

Identiteit

Categorie

Metabool

CAS-nr.

geen gegevens

910463-68-2

Molecuulmassa

geen gegevens

4113.6 g/mol

Halfwaardetijd

geen gegevens

165 h

Sequentie

geen gegevens

modifiziertes GLP-1-Analogon (31 AS) mit C18-Fettsäure-Linker

Werkingsmechanisme

Petrelintide

As an amylin analogue, petrelintide acts through amylin receptors, promoting satiety and slowed gastric emptying — a satiety pathway independent of the GLP-1 axis.

Semaglutid

Long-acting agonist at the GLP-1 receptor. Structurally a modified glucagon-like peptide 1 whose long half-life is achieved via a fatty-acid side chain and reversible albumin binding. Acts centrally on satiety and peripherally on glucose-dependent insulin secretion and delayed gastric emptying.

Bewijsbasis

Hoogste bewijs

Humane RCT

Studies

waarvan bij mensen

Geregistreerde effecten

Openstaande tegenstrijdigheden

Gedocumenteerde bijwerkingen

Juridische status

Country	Petrelintide	Semaglutid
Zwitserland	—	Op recept
Duitsland	Niet goedgekeurd	Op recept
Verenigde Staten	Niet goedgekeurd	Op recept

Volledige vermeldingen

Petrelintide

Volledige vermelding →

Semaglutid

Volledige vermelding →

Frequently asked questions

What is the difference between Petrelintide and Semaglutid?: Petrelintide is classified as "Metabool", while Semaglutid is classified as "Metabool". Petrelintide: Petrelintide is a long-acting amylin analogue (Zealand Pharma, with Roche) for once-weekly subcutaneous use — developed for weight management with a focus on strong tolerability. Semaglutid: Long-acting GLP-1 receptor agonist. Approved as a medicinal product for type-2 diabetes (Ozempic, Rybelsus), chronic weight management (Wegovy) and cardiovascular risk in obesity. One of the best-studied substances on this platform — many large human RCTs. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Petrelintide or Semaglutid?: The highest available evidence level is "Humane RCT" for Petrelintide and "Humane RCT" for Semaglutid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Petrelintide and Semaglutid in Germany and the United States?: Duitsland: Petrelintide — Niet goedgekeurd, Semaglutid — Op recept. Verenigde Staten: Petrelintide — Niet goedgekeurd, Semaglutid — Op recept. These are factual summaries with source and review date on the individual pages.

Country

Petrelintide

Semaglutid

Zwitserland

—

Op recept

Duitsland

Niet goedgekeurd

Op recept

Verenigde Staten

Niet goedgekeurd

Op recept

Frequently asked questions

What is the difference between Petrelintide and Semaglutid?

Petrelintide is classified as "Metabool", while Semaglutid is classified as "Metabool". Petrelintide: Petrelintide is a long-acting amylin analogue (Zealand Pharma, with Roche) for once-weekly subcutaneous use — developed for weight management with a focus on strong tolerability. Semaglutid: Long-acting GLP-1 receptor agonist. Approved as a medicinal product for type-2 diabetes (Ozempic, Rybelsus), chronic weight management (Wegovy) and cardiovascular risk in obesity. One of the best-studied substances on this platform — many large human RCTs. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Petrelintide or Semaglutid?

The highest available evidence level is "Humane RCT" for Petrelintide and "Humane RCT" for Semaglutid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Petrelintide and Semaglutid in Germany and the United States?

Duitsland: Petrelintide — Niet goedgekeurd, Semaglutid — Op recept. Verenigde Staten: Petrelintide — Niet goedgekeurd, Semaglutid — Op recept. These are factual summaries with source and review date on the individual pages.